Mauna Kea Technologies (ALMKT) H1 2025 earnings summary

Executive summary

• Achieved a key milestone in financial restructuring, including a major reduction in debt and a new capital increase plan, with court-supervised safeguard proceedings initiated in March 2025.

• Revenue for H1 2025 was €3.7M, down 5% year-over-year, with strong US growth offset by declines in Europe due to restructuring.

• Commercial momentum in the US was maintained, with Cellvizio adoption accelerating and new AI patents secured.

• The company is focused on reaching profitability by 2027, supported by cost reductions and improved sales productivity.

• Net loss remained stable at €4.7M compared to the same period last year.

Financial highlights

• Operating loss improved to -€3.0M from -€3.7M, reflecting a 32% reduction year-over-year due to strict expense control.

• System sales rose 19% year-over-year, while consumables and services fell 31% and 20%, respectively.

• Gross margin on product sales was 63%, down from 66% due to new US tariffs.

• Cash and equivalents were €0.7M at June 30, 2025, later strengthened by a €1.8M convertible bond issue.

• US sales grew significantly, now representing 70-80% of total revenue, while other regions faced temporary declines.

Outlook and guidance

• Profitability targeted for 2027, based on prudent assumptions, disciplined cost control, and continued US growth.

• Focus for H2 2025 is on US growth, international expansion (notably Australia), regulatory milestones in France, and new strategic partnerships.

• Commercial team expansion planned to accelerate growth, with expected rapid ROI from new hires.

• Anticipates new market entries and reimbursement approvals, especially in France and China.

• Ongoing strategic partnership discussions and a target to achieve profitability by 2027.